{"id":22674,"date":"2025-01-23T15:55:11","date_gmt":"2025-01-23T07:55:11","guid":{"rendered":"https:\/\/flcube.com\/?p=22674"},"modified":"2025-01-23T16:04:55","modified_gmt":"2025-01-23T08:04:55","slug":"simnova-orna-expand-partnership-to-develop-bcma-targeted-rna-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22674","title":{"rendered":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies"},"content":{"rendered":"\n<p>Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna&#8217;s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.<\/p>\n\n\n\n<p><strong>Partnership Details<\/strong><br>Under the agreement, Simnova will conduct the research and development and commercialization of in vivo panCar cell therapies targeting BCMA in Greater China. Orna will retain all rights for development and commercialization in the rest of the world. Each party will receive an upfront payment within their respective licensed territories and is eligible for clinical development, regulatory, and commercialization milestones, as well as royalties on any approved products derived from the collaboration.<\/p>\n\n\n\n<p><strong>Previous Collaboration<\/strong><br>The two companies first partnered in January 2023, when Orna granted Simnova exclusive rights to develop and commercialize Orna\u2019s in vivo cell therapy products in the Greater China region, including the CD19-targeted isCAR program ORN-101. This latest expansion underscores the ongoing commitment of both parties to advancing innovative therapeutic solutions.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>With BCMA now included as a target, the partnership between Simnova and Orna Therapeutics is poised to further enhance the development of RNA-based therapeutics. This collaboration positions both companies to address significant unmet medical needs and improve patient outcomes through next-generation treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":22679,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,3261,3260],"class_list":["post-22674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-orna-therapeutics","tag-simnova-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies\" \/>\n<meta property=\"og:description\" content=\"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-23T07:55:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-23T08:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies\",\"datePublished\":\"2025-01-23T07:55:11+00:00\",\"dateModified\":\"2025-01-23T08:04:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674\"},\"wordCount\":249,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2314-png.avif\",\"keywords\":[\"Cell-therapy\",\"Orna Therapeutics\",\"Simnova Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22674#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22674\",\"name\":\"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2314-png.avif\",\"datePublished\":\"2025-01-23T07:55:11+00:00\",\"dateModified\":\"2025-01-23T08:04:55+00:00\",\"description\":\"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22674\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2314-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2314-png.avif\",\"width\":1080,\"height\":540,\"caption\":\"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22674","og_locale":"en_US","og_type":"article","og_title":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies","og_description":"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.","og_url":"https:\/\/flcube.com\/?p=22674","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-23T07:55:11+00:00","article_modified_time":"2025-01-23T08:04:55+00:00","og_image":[{"width":1080,"height":540,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies","datePublished":"2025-01-23T07:55:11+00:00","dateModified":"2025-01-23T08:04:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22674"},"wordCount":249,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","keywords":["Cell-therapy","Orna Therapeutics","Simnova Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22674#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22674","url":"https:\/\/flcube.com\/?p=22674","name":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22674#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","datePublished":"2025-01-23T07:55:11+00:00","dateModified":"2025-01-23T08:04:55+00:00","description":"Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its strategic partnership with Cambridge, Massachusetts-based Orna Therapeutics. The collaboration now includes BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. This partnership aims to leverage Orna\u2019s groundbreaking circular RNA (oRNA) technology and Simnova\u2019s expertise in cell therapy to deliver transformative treatments for patients worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22674"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22674#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","width":1080,"height":540,"caption":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2314-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22674\/revisions"}],"predecessor-version":[{"id":22680,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22674\/revisions\/22680"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22679"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}